Aclaris Therapeutics' ATI-2138 Demonstrates Rapid Hair Regrowth in Murine Model of Alopecia Areata

Aclaris Therapeutics' novel ITK/JAK3 inhibitor ATI-2138 has shown rapid and sustained hair regrowth in a validated murine model of alopecia areata. The drug outperformed ritlecitinib in a reversal model of alopecia universalis, the most severe AA phenotype. ATI-2138 demonstrated rapid hair regrowth at week 2 and reached near peak effect at week 4, outperforming ritlecitinib. The drug's dual targeting of ITK and JAK3 may provide a potent and complete anti-inflammatory response.